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Abstract
Nitric oxide production, catalyzed by nitric oxide synthase (NOS), should be strictly regulated to allow embryo implantation.
Thus, our first aim was to study NOS activity during peri-implantation in the rat uterus. Day 6 inter-implantation sites
showed lower NOS activity (0.1960.01 pmoles L-citrulline mg prot
21 h
21) compared to days 4 (0.3460.03) and 5
(0.3560.02) of pregnancy and to day 6 implantation sites (0.3360.01). This regulation was not observed in
pseudopregnancy. Both dormant and active blastocysts maintained NOS activity at similar levels. Anandamide (AEA), an
endocannabinoid, binds to cannabinoid receptors type 1 (CB1) and type 2 (CB2), and high concentrations are toxic for
implantation and embryo development. Previously, we observed that AEA synthesis presents an inverted pattern compared
to NOS activity described here. We adopted a pharmacological approach using AEA, URB-597 (a selective inhibitor of fatty
acid amide hydrolase, the enzyme that degrades AEA) and receptor selective antagonists to investigate the effect of AEA on
uterine NOS activity in vitro in rat models of implantation. While AEA (0.7060.02 vs 0.4060.04) and URB-597 (1.0860.09 vs
0.8360.06) inhibited NOS activity in the absence of a blastocyst (pseudopregnancy) through CB2 receptors, AEA did not
modulate NOS on day 5 pregnant uterus. Once implantation begins, URB-597 decreased NOS activity on day 6 implantation
sites via CB1 receptors (0.2560.04 vs 0.4060.05). While a CB1 antagonist augmented NOS activity on day 6 inter-
implantation sites (0.1760.02 vs 0.2760.02), a CB2 antagonist decreased it (0.1760.02 vs 0.1260.01). Finally, we described
the expression and localization of cannabinoid receptors during implantation. In conclusion, AEA levels close to and at
implantation sites seems to modulate NOS activity and thus nitric oxide production, fundamental for implantation, via
cannabinoid receptors. This modulation depends on the presence of the blastocyst. These data establish cannabinoid
receptors as an interesting target for the treatment of implantation deficiencies.
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Introduction
About half of all conceptuses are lost before the expected term,
thus making human reproduction a rather inefficient process [1].
In vitro fertilization techniques (IVF) also result in a high frequency
of spontaneous abortions [1]. For IVF, the clinical pregnancy rate
per aspiration and per transfer is 26.0 and 29.5%, respectively [2].
Implantation seems to be the bottle neck for the improvement of
these techniques.
Several reports point to a role for nitric oxide (NO) and
anandamide in implantation. NO is produced by conversion of
oxygen and L-arginine to NO and L-citrulline. This reaction is
catalyzed by nitric oxide synthase (NOS), of which there are three
different isoforms: endothelial nitric oxide synthase (eNOS),
inducible nitric oxide synthase (iNOS) and neuronal nitric oxide
synthase (nNOS) in almost all types of cells [3]. Purcell and
colleagues described that at implantation labelled iNOS cells are
within the decidua and the ectoplacental cone, while eNOS is
localized in vessels of the primary decidual zone [4]. Both iNOS
and eNOS expression are higher at implantation sites. Neuronal
NOS is localized mainly in the mesometrium and myometrium
and does not appear to change throughout peri-implantation.
Moreover, in utero administration of L-NAME, a non selective
NOS inhibitor, or of NO-donors during the pre-implantation
phase reduces implantation rates [5,6]. All together these
evidences strongly suggest that optimal levels of NO are crucial
for endometrial function and embryo implantation.
Anandamide (N-arachidonoylethanolamine, AEA) is an endog-
enously produced cannabinoid-like lipid mediator [7] that mimics
several actions of the natural Cannabis sativa component D
9-
tetrahydrocannabinol, which accounts for the majority of the
reproductive hazards in marijuana users [8,9]. AEA binds to and
activates two classical G protein (Gi/o)–coupled cell-surface
cannabinoid receptors, cannabinoid receptor type 1 (CB1) and
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are detrimental for implantation [12] and embryo development
[13]. However, the fact that the uterus contains the highest
concentrations of AEA yet discovered in mammalian tissues
[12,14] suggests that it might play a role in reproduction. The
groups of Paria et al. and Guo et al. were the first ones to report
that the mouse uterus has the capacity to synthesize AEA [14,15].
We have recently found that the rat uterus also has an AEA-
synthesizing capacity [16], and as previously described in mice
[14,15], AEA production in the rat uterus is spatiotemporally
regulated during implantation, being lower in the receptive uterus
and at implantation sites.
In other systems different from the uterus, it has been described
that while CB1 activates NOS, CB2 inhibits it [17,18].
Particularly, in human endothelial cells from various blood vessels,
CB1 immunoreactive components are present as is its coupling to
anandamide-stimulated NOS-derived NO production [19]. The
modulation of vascular diameter and vascular tone by NO
represents a crucial point of interest in implantation, and
interactions between NO and AEA could be of importance. We
have previously observed that AEA increases uterine and deciduas
NO production through iNOS activation in a mouse model of fetal
resorption [20,21].
Based on the above evidence, the principal aim of the present
work was to study in an in vitro system if AEA modulated NOS
activity at implantation and if the blastocyst participates of this
interaction. Pseudopregnancy and ovariectomy-induced delayed
implantation models were used as tools to understand the relative
roles played by the embryo. The fact that AEA differently
regulated NOS activity through CB1 and CB2 receptors and that
this modulation depended on the presence of the blastocyst during
implantation, contributes to better understand the significance of
ligand – receptor signalling with AEA and NO as possible effectors
in coordinating the series of events that leads to a successful
pregnancy.
Materials and Methods
Ethics Statement
The experimental procedures reported here were approved by
the Animal Care Committee of the Centro de Estudios Farm-
acolo ´gicos y Bota ´nicos (CEFYBO - CONICET) and by the
Institutional Committee for the Care and Use of Laboratory
Animals, Permit Number: 2550/2010 (CICUAL, Comite ´ Institu-
cional para el Cuidado y Uso de Animales de Laboratorio) from
the Facultad de Medicina (Universidad de Buenos Aires), and were
carried out in accordance with the Guide for Care and Use of
Laboratory Animals (NIH). All animals were provided by the
animal facility of the Facultad de Odontologı ´a (Universidad de
Buenos Aires).
Animals
Female rats of the Wistar strain were housed in group cages
under controlled conditions of light (12 h light, 12 h dark) and
temperature (23–25uC). Animals received food and water ad
libitum. Where mentioned, animals were sacrificed in a carbon
dioxide chamber and all efforts were made to minimize suffering.
Virgin female rats were mated with fertile males of the same
strain. The morning the spermatozoa were observed in the vaginal
fluid was defined as day 1 of pregnancy. Under the conditions of
our animal facilities, spontaneous term labor occurs on day 22 of
gestation. Blastocysts enter the uterus lumen between days 4 and 5
of gestation and implantation begins during the afternoon of day 5.
Rats on days 4 to 6 of pregnancy (peri-implantation) were
sacrificed at 9:00–10:00 in the morning. On day 6 of pregnancy
distinct macroscopically visible uterine swellings indicated the
implantation sites. Uterine horns of rats on days 4–6 of pregnancy
were excised and uterine horns on day 6 were separated into
implantation and inter-implantation sites.
Different methods of manipulating pregnancy-related uterine
changes (pseudopregnancy and ovariectomy-induced delayed
implantation) were used as tools to understand the relative roles
played by the embryo and ovarian hormones in modulating the
changes in NOS activity in the pregnant rat. These models were
previously established [16].
Briefly, for delayed implantation, rats were ovariectomized at
9:00–10:00 on day 4 of pregnancy. To maintain the implantation
delay, rats were injected with progesterone (8 mg kg
21, s.c.) on
days 5 and 6 of pregnancy. On day 7 of gestation, females were
divided randomly into two groups and treated respectively with
progesterone (8 mg kg
21, s.c.) or 17b-estradiol (0.4 mg kg
21, s.c.).
Steroids were dissolved in 0.2 mL of corn oil. Rats were sacrificed
at 9:00–10:00 on day 8 and their uteri were collected and stored at
270uC until used.
Pseudopregnancy (psp) could be induced in female rats treated
with equine chorionic gonadotrophin (PMSG). In this model, the
uterus undergoes all the normal changes that prepare it for
implantation, but no embryos are present in the uterine lumen.
Prepuber rats (25–28 days of age) received 50 iu PMSG i.p.
[16,22]. Day 1 of pseudopregnancy was considered 24 h after the
injection. Females were sacrificed on days 4, 5 and 6 of psp.
PMSG was disolved in saline.
Total NOS enzyme assay
NOS enzyme activity was quantified by the modified method of
Bredt & Snyder [23] which measures the conversion of [
14C]-L-
arginine into [
14C]-L-citrulline. NO and L-citrulline are produced
in equimolar amounts.
Uterine slices were weighted and where mentioned, they were
incubated with different drugs (AEA, SR141716A, SR144528 or
URB-597) in Krebs Ringer Bicarbonate solution (145 mM Na
+,
6m M K
2+, 2 mM Ca
2+, 1.3 mM
1 Mg
2+, 126.1 mM Cl
2,
25.3 mM HCO3
2, 1.3 mM SO4
22, 1.2 mM PO4
22) with
11 mM glucose. Then, tissues were homogenized (Ultra Turrax,
T25 basic, IKA Labortechnik) and incubated at 37uCi na n
HEPES buffer (20 mM HEPES, 25 mM L-valine, 0.45 mM
CaCl2, 100 mM DTT) containing 0.6 mCi ml
21 [
14C]-L-arginine
and 0.5 mM NADPH. After 15 min of incubation, samples were
centrifuged for 15 min at 12000 g. They were then applied to a
1 mL DOWEX AG500-X column (Na
+-form) and [
14C]-L-
citrulline was eluted in 2.5 mL of distilled water. The [
14C]-L-
citrulline radioactivity was measured by liquid scintillation
counting. Protein concentration was determined by the Bradford
method [24]. Enzyme activity was expressed as pmol L-citrulline
mg protein
21 h
21.
Polymerase chain reaction analysis
Uterine total RNA from rats on day 5 of pseudopregnancy was
isolated using Trizol reagent according to the manufacturer’s
recommendations. RNA was thawed on ice, quantified spectro-
phometrically at 260 and 280 nm and RNA quality assessed using
ethidium bromide-stained gels. RNA with a 260:280 ratio of 1.8
and above was further treated with RNAse free DNAse I to digest
contaminating genomic DNA. First strand cDNA was synthesized
from total RNA (3 mg) using Moloney murine leukemia virus
reverse transcriptase (MMLV-RT) and random primers according
to the manufacturer’s recommendations (Invitrogen, Buenos Aires,
Argentina) in the presence of ribonuclease inhibitor. After first
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with specific intron spanning primers. PCR primers are specified
in Table 1. The PCR conditions in all cases started with a
denaturation step at 94uC for 5 min and followed by up to 30
cycles of denaturation, annealing and primer extension (Table 1).
PCR products were resolved in 2% agarose gels and visualized by
ethidium bromide staining. Photographs were taken using a digital
camera Olympus C-5060 and analyzed using the Image J (open
source) software package. Data were expressed as the relative
amount of CB1 or CB2 versus b-actin mRNA.
Real Time RT-PCR analysis
RNA messenger expression in the uterus from rats pregnant on
days 4, 5 and 6 of gestation was analyzed by real time RT-PCR.
Real time RT-PCR was performed on RG6000 (Corvette) using
Master Mix, gene specific primers (Table 1) and 5 ml of cDNA as
template. The PCR conditions in all cases started with a
denaturation step at 94uC for 5 min and followed by up to 40
cycles of denaturation, annealing and primer extension (Table 1).
CB1 and CB2 mRNA levels were corrected to the levels of rat b-
actin using the 2-
DDCt method [25] and normalized to the ratio
produced in the samples from the day 4 of pregnancy.
CB1 and CB2 identification by western-blotting
Cannabinoid receptors proteins from the uterus of pregnant and
psp rats were determined by western blot analysis using a CB1 or a
CB2 specific antibody. Uterine slices frozen at 270uC were
incubated in triple-detergent buffer (PBS pH=7.4 with 0.02% w/v
sodium azide, 0.1% w/v SDS, 1% v/v Nonidet P-40, 0.5% v/v
sodium deoxycholate) containing 10 mgm l
21 leupeptin, 2 mgm l
21
aprotinin, 100 mgm l
21 soybean-trypsin inhibitor, 1 mmol l
21
EDTA, 1 mg ml
21 benzamidine, 10 mgm l
21 DTT and
1m gm l
21 caproid acid. Tissues were homogenized (Ultra Turrax,
T25 basic, IKA Labortechnik), sonicated for 30 s (Ultrasonic Cell
Disrupter, Microson, Heat systems Inc.) and centrifuged for
30 min at 12000 g. Protein determination was assayed by the
Bradford method [24] using bovine serum albumin as standard.
Equal amount of proteins (100 mg/lane) were separated in 10%
(CB1) or 12% (CB2) w/v SDS-PAGE and subsequently
transferred to nitrocellulose membranes. Non-specific binding
sites of the membranes were blocked using 5% w/v dried non-
fat milk in PBS pH=7.4. Non-specifically bound antibody was
removed by washing three times with PBS containing 0.1% v/v
Tween-20. Membranes were incubated with primary CB1
(1:250 in PBS) or CB2 (1:200 in PBS) antibodies followed by
a goat anti-rabbit horseradish peroxidase-conjugated IgG
(1:8000 for CB1 and 1:5000 for CB2 in PBS containing 5%
w/v dried non-fat milk). Immunoreactive bands were visualized
and photographed using Image Quant Software (GE Health-
care, Buenos Aires, Argentina). Brain and spleen homogenates
were used as positive controls for CB1 and CB2 respectively.
Immunoreactive specificity was assessed by omitting the first
antibodies. Protein bands were identified by molecular weight
markers. b-actin was used as loading control. The intensity of
bands was determined using the Image J software package (open
source). Results were expressed as relative optic density CB1 or
CB2 receptor/b-actin.
Light microscopy and immunohistochemistry
Uteri from pregnant rats on days 4, 5 and 6 of gestation were
removed and fixed overnight in paraphormaldehyde 4% in
phosphate-buffered saline (PBS) 0.1 M (pH 7.4). The tissue
sections were dehydrated and embedded in paraffin. The paraffin
block was orientated to enable the implantation sites to be
sectioned transversally. Sections of 5 mm were made by a
microtome (Leica RM 2125, Wetzlar, Germany) and mounted
on 2% silane-coated slides. The sections were stained with
hematoxylin–eosin, and observed by light microscopy (Nikon
Eclipse 200, NY, USA) to determine general tissue morphology
and to identify the different cell types present. For immunohisto-
chemistry studies, the samples were blocked of endogenous
peroxidase with hydrogen peroxide 0.3% v/v in methanol for
10 min and rinsed with PBS. The slides were pre-incubated with
non-immune rabbit serum diluted in PBS (1:100) in a humidity
chamber at room temperature for 1 h. Then, the slices were
incubated at 4uC overnight in a humidity chamber with a
polyclonal rabbit antibody directed against CB1 or CB2 (1:50 in
PBS). The immunoperoxidase technique was then performed
following the protocol for the RTU Vectastain kit (Vector,
Peterborough, UK). The antigen was revealed by diaminobenzi-
dine (DAB, Vector, Peterborough, UK). Finally, the sections were
dehydrated, counterstained and mounted for observation. In each
experimental immunohistochemical run, sections from all days of
pregnancy (days 4 to 6) were included.
Drugs and chemicals
[
14C]-L-arginine monohydrocloride (specific activity 317 mCi
mmol
21) was provided by Amersham Corporation (Arlington
Heights, IL, USA). Optiphase-3 scintillation solution was from
Perkin Elmer (ETC, Buenos Aires, Argentina). Luminol (Fluka), p-
coumaric acid (Fluka), anandamide, 17b-estradiol, progesterone,
NADPH, HEPES,valine,Dowex AG500-X column(Na
+-form) and
western blot detergents and inhibitors were purchased to Sigma
Chemical Company (Buenos Aires, Argentina) and Bio Rad
(Tecnolab, Buenos Aires, Argentina). Chemiluminescence detection
solutions were from Romek Laboratories (Buenos Aires, Argentina).
Trizol reagent was from Genbiotech (Buenos Aires, Argentina).
RNAse free DNAse I, Moloney Murine Leukemia virus reverse
transcriptase (MMLV-RT) and random primers were purchased
from Invitrogen (Buenos Aires, Argentina). Master Mix for real time
RT-PCR was from Promega (Biodynamics, Buenos Aires, Argen-
tina). Polyclonal rabbit antibody against CB1 was from Biomol
(Enzo Life Sciences, Miami, USA). CB2 antibody was purchased
from Abcam (Migliore Laclaustra, Buenos Aires, Argentina). Goat
anti-rabbithorseradishperoxidase-conjugated IgGwasfromJackson
ImmunoResearch Laboratories, Inc. (SERO-IMMUNO DIAG-
NOSTICS, INC, Tucker, GA, USA). PMSG (equine chorionic
gonadotrophin, NOVORMONH) was kindly provided by Syntex
Table 1. Primer sequences and PCR conditions.
mRNA
target Primers Conditions
b-actin Sense 59-GCCATGTACGTAGCCATCC-39 94uC, 5 min
Antisense 59-CTCTCAGCTGTGGTGGTGAA-39 59uC, 30 seg
72uC, 1 min
Cb1 Sense 59-CGTAAAGACAGCCCCAATGT-39 94uC, 5 min
Antisense 59-TACCTGTCGATGGCTGTGAG-39 59uC, 30 seg
72uC, 1 min
Cb2 Sense 59-CCTGTTGAAGATCGGCAGCG-39 94uC, 5 min
Antisense 59-GGTAGGAGATCAACGCCGAG-39 57uC, 30 seg
72uC, 1 min
Cb1: cannabinoid receptor type-1; Cb2: cannabinoid receptor type-2.
doi:10.1371/journal.pone.0018368.t001
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(SR141716A, N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophe-
nyl)-4-methyl-3-pyrazole carboxamide) [26] and CB2 selective
antagonist (SR144528, N-[1(S)-endo-1,3,3-trimethyl-bicyclo[2.2.1]-
heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methyl-benzyl)-pyr-
azole-3-carboxamide) [27] were kind gifts from Sanofi-Aventis
Recherche (Montpellier, France). URB-597 was from Cayman
Chemical Company (Migliore Laclaustra, Buenos Aires, Argentina).
All other chemicals were analytical grade.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism
Software (San Diego, CA, USA). Comparisons between values of
different groups were performed using one way ANOVA (analyze
of variance). Significance was determined using Tukey’s multiple
comparison tests for unequal replicates. A number of 4–6 animals
were used for each treatment. All values presented in this study
represent means 6 S.E.M. Differences between means were
considered significant when p was 0.05 or less.
Results
NOS activity was modulated during peri-implantation
Uterine tissue from pregnant rats presented detectable NOS
activity in all the days analyzed (Figure 1A). NOS activity
remained constant on days 4 and 5 of gestation and at
implantation sites from day 6 of gestation. However, a significant
decrease happened at inter-implantation sites from day 6. Thus,
NOS activity was higher in the receptive pre-implantation uterus
and at the sites of embryo implantation compared to the inter-
implantation sites.
As NOS activity was differentially regulated between implanta-
tion and inter-implantation sites, we decided to investigate if this
modulation was supported by a crosstalk between the blastocyst and
the uterus and/or by ovarian hormones. Thus, we studied NOS
activity in the delayed implantation model and during pseudopreg-
nancy (see methods). In delayed implantation rats, there was no
difference between the treatments with 17b-estradiol, that activated
implantation, or progesterone, that maintained the embryo and the
uterus quiescent (Figure 1B). In pseudopregnancy, the uterus
underwent the same changes observed in control pregnancies, but
embryos were absent. Results show that in the absence of a
blastocyst, NOS activity remained constant during psp and there
was no drop as observed in normal gestation (Figure 1C).
CB1 and CB2 mediated AEA differential effects on NOS
activity
Previous results from Guo et al. [14], Paria et al. [15] and our
group [16] demonstrate that on day 6 of pregnancy, implantation
sites show lower AEA synthesis compared to inter-implantation
sites. Since AEA synthesis presents an inverted pattern compared
to NOS activity described above, we hypothesized that low AEA
levels near to and at implantation sites might increase NOS
activity, while high AEA levels at inter-implantation sites might
decrease it. We decided to investigate this issue and to determine
the relative role of the blastocyst in the interaction AEA-NO.
In order to determine optimal incubation conditions, a
concentration-response curve was carried out using day 5 psp
uterine tissue. Incubation during 15 min with AEA 10
29 M,
10
28 M and 10
27 M inhibited NOS activity (Figure 2). AEA
10
26 M and 10
210 M did not modify NOS activity. The
incubation time was selected due to AEA short half life [28]. In
subsequent experiments we incubated the tissues with AEA
10
29 M, which is the physiological concentration reported in
different reproductive fluids [12,14,29] and the lowest concentra-
tion that showed effect.
To study which receptors were mediating AEA effect in the
pseudopregnant model, uterine strips from day 5 of psp were pre-
Figure1.NOSactivityintherat uterus duringperi-implantation.
NOS activity was determined (A) on days 4 (d4), 5 (d5) and 6 of gestation
(implantation (d6IM) and inter-implantation sites (d6II) were assessed
separately on day 6 of pregnancy), (B) in the delayed implantation model
and (C) during pseudopregnancy (psp). NOS activity is expressed as
pmoles citrulline mg prot
21 h
21.a :p ,0,001 vs the rest. N=4–6 for each
point. d4: day 4, d5: day 5, d6: day 6, IM: implantation sites, II: inter-
implantation sites.
doi:10.1371/journal.pone.0018368.g001
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210 M (a CB1 selective
antagonist) or SR144528 10
210 M (a CB2 selective antagonist).
Afterwards tissues were incubated during 15 min with AEA
10
29 M in the presence of the antagonists. Based on both binding
and functional data, SR141716A and SR144528 at the selected
concentration are highly potent and selective antagonists for the
CB1 and CB2 receptors respectively [30,31]. Nor SR141716A
10
210 M neither SR144528 10
210 M incubated alone presented
any effect on NOS activity (Table 2). While SR141716A 10
210 M,
the CB1 selective antagonist, did not modify AEA action,
SR144528 10
210 M, the CB2 selective antagonist, reverted AEA
inhibitory effect on NOS activity in the pseudopregnant model
(Figure 2B). To determine the effect of endogenous AEA, uterine
strips from day 5 of psp were incubated for 30 min with URB-597,
a FAAH selective inhibitor. As FAAH is the enzyme that degrades
AEA, the treatment with URB-597 increases AEA endogenous
concentration. We observed that URB-597 10
29 M inhibited
NOS activity (Figure 2C). As previously observed for exogenous
AEA, pre-incubation for 30 min with SR144528 10
210 M, the
selective CB2 antagonist, reversed URB-597 inhibitory effect on
NOS activity. Thus, in the absence of the blastocyst, AEA
inhibited NOS activity through CB2 receptors.
When the uterus obtained from rats pregnant on day 5 were
incubated with AEA 10
29 M, it did not exert any effect on NOS
activity (Figure 3A). In contrast to what was observed on day 5 of
psp, AEA was not able to regulate NOS activity just before the
blastocyst begins the process of implantation (day 5 of pregnancy).
Other authors [14,15] and our group [16] have previously
observed that mouse and rat implantation sites show low AEA
synthesis, while it is increased at the inter-implantation sites. Thus,
implantation sites from day 6 pregnant rats were incubated for
30 min with URB-597 10
29 M to increase endogenous AEA
levels. We observed that URB-597 diminished NOS activity and
that this effect was completely reverted when the implantation sites
were pre-incubated for 30 min with the selective CB1 antagonist
SR141716A 10
210 M (Figure 3B). In order to study endogenous
AEA effect on day 6 inter-implantation sites, this tissue was
incubated for 30 min with SR141716A 10
210 M or SR144528
10
210 M. We observed that while CB1 selective antagonist
(SR141716A 10
210 M) increased NOS activity, the CB2 selective
antagonist (SR144528 10
210 M) decreased it (Figure 3C). The
incubation with both CB1 and CB2 antagonists did not modify
NOS activity with respect to the control. These results showed that
once implantation begins, at the implantation sites, AEA inhibited
NOS activity through CB1 receptors. However, at the inter-
implantation sites, AEA presented a dual effect: it inhibited NOS
activity through CB1, while it increased NOS via CB2 receptors.
Cannabinoid receptors expression and localization in the
rat uterus
Finally, we decided to investigate CB1 and CB2 expression and
localization in order to better understand the relative roles played
by these receptors in the effect of AEA on NOS activity. Also to
our knowledge, there are still no reports about the expression of
CB2 protein in the rat uterus during the peri-implantation period,
and here we found that CB2 mediated some of the actions of AEA
on NOS activity.
CB1 messenger was amplified by real time RT-PCR in control
pregnancy and identified by RT-PCR in pseudopregnancy as a
single band at 101 bp. CB1 messenger was clearly regulated
showing a significant decrease at the implantation sites from day 6
of gestation (p,0.01) compared with days 4 and 5 of pregnancy
and with the inter-implantation sites from day 6 (Figure 4A). CB1
protein was detectable as a single band at the expected molecular
mass of 51 KDa during pregnancy [32]. However, it seemed not
to be regulated in the rat uterus as was CB1 mRNA (Figure 4B).
On day 5 of pseudopregnancy, both CB1 messenger and protein
were detected (Figure 4C and 4D).
With respect to CB1 localization in pregnancy, it was detectable
in the endometrium obtained from rats on days 5 and 6 of
gestation, but we were not able to detect it on day 4 of pregnancy
(Figure 5A). On day 5, CB1 was immunoreactive in the apical
membrane of the glandular epithelium (Figure 5B). While in the
implantation sites CB1 was localized to the apical membrane and
subapical cytoplasm of the luminal epithelium (Figure 5C), in the
inter-implantation sites it was also detected in the glandular
epithelium of the endometrium (Figures 5D and 5E).
CB2 messenger was also amplified by real time RT-PCR at
pregnancy and identified by RT-PCR in psp as a single band at
182 bp. During peri-implantation, we observed that CB2
messenger decreased on days 5 and 6 compared to day 4
(p,0.001) and that there was no difference between the
implantation and the inter-implantation sites (Figure 6A). CB2
protein expression was readily detectable at pregnancy and it
appeared as a single band at approximately 37 KDa (Figure 6B).
One immunoreactive band of higher molecular weight was also
observed that most likely corresponded to a glycosylated form of
the receptor [32]. CB2 protein expression increased on days 5 and
6 of gestation when compared with day 4 of pregnancy (p,0.05,
Figure 6B). On day 6, after the blastocyst is attached, there were
no spatial differences between the implantation and the inter-
implantation sites. On day 5 of pseudopregnancy, CB2 messenger
and protein were readily detected (Figures 6C and 6D).
Finally, we decided to investigate the localization of CB2 during
pregnancy. Although CB2 protein was readily detectable in the
endometrium on days 4 and 6 of gestation, we were not able to
observe CB2 expression on day 5 of gestation (Figure 7C). On day
Table 2. Effect of cannabinoid receptors selective antagonists
on NOS activity.
NOS activity
control 0.9060.10
SR141716A 10
210 M 0.9060.10
SR141716A 10
29 M 0.7560.10
SR144528 10
210 M 0.9060.20
SR144528 10
29 M 0.8060.20
Cannabinoid receptors selective antagonists SR141716A (type 1, CB1) or
SR144528 (type 2, CB2) were incubated alone for 30 min with day 5
pseudopregnant rat uterus and NOS activity was determined. Results are
expressed as pmoles citrulline mg prot
21 h
21. N=4–6 for each point.
doi:10.1371/journal.pone.0018368.t002
Figure 2. Effect of AEA on NOS activity on day 5 of pseudopregnancy. (A) Concentration-response curve of anandamide (AEA). (B) Effect of
selective cannabinoid receptors antagonists on AEA inhibitory action. (C) Effect of URB-597 (a selective inhibitor of FAAH, the enzyme that degrades
AEA) and selective cannabinoid receptors antagonists. NOS activity is expressed as pmoles citrulline mg prot
21 h
21.a :p ,0,001 vs the rest,
b: p,0.001 vs the rest, c: p,0.05 vs the rest. N=4–6 for each point. antCB1: CB1 selective antagonist (SR141716A), antCB2: CB2 selective antagonist
(SR144528).
doi:10.1371/journal.pone.0018368.g002
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(Figure 7B) epithelium both in the apical membrane and in the
subapical cytoplasm. In the implantation sites, CB2 was observed
only in the luminal epithelium at the apical membrane and
subapical cytoplasm (Figure 7D). In the inter-implantation sites
from day 6 of gestation, CB2 was localized to the apical membrane
and subapical cytoplasm in the luminal epithelium (Figure 6E) and
to the apical membrane in the glandular epithelium (Figure 6F).
No staining was observed in the luminal or glandular epithelium
when the first antibodies were omitted (Figures 6G).
Discussion
In the present work we observe that in the rat uterus NOS
activity is increased during pre-implantation and at implantation
sites compared to inter-implantation sites. Interestingly, AEA
modulates NOS activity through cannabinoid receptors and this
regulation depends on the presence of the blastocyst. Also, we
describe for the first time the expression and localization of CB1
and CB2 receptors during implantation in the rat uterus.
Regulation of NOS activity described here coincides with
previously reported iNOS and eNOS expression in early gestation
[4,33,34]. The fact that NOS activity is higher at implantation
sites suggests that NO has a role specifically where blastocysts
attach to the endometrium. Purcell and colleagues described that
eNOS and iNOS proteins are localized in the endometrial decidua
and stromal cells as well as in the myometrium and blood vessels
that irrigate the uterine tissue [4]. Neuronal NOS is restricted to
the myometrium. Thus, it is possible that blastocysts might be
increasing NO production by regulating eNOS and iNOS, the
isoforms that are expressed in the cellular types in direct contact
with the embryo.
Two processes are fundamental during the establishment of
pregnancy: the increase in vascular permeability and decidualiza-
tion. NO is a potent vasodilator and a well known mediator of
vascular permeability [35]. Besides, NO augments the expression
of some specific matrix metalloproteinases [36] which are known
to participate in tissue remodeling. Thus, our results reinforce the
notion that increased NOS activity in the receptive uterus and
specifically at implantation sites might be contributing to
neovascularization and tissue remodeling during trophoblast
invasion.
Novaro and colleagues described that NOS activity increases in
pre-implantation days and then declines on day 6 of gestation [5].
Differences with our results could be due to the way in which
results were expressed and because we differentiated implantation
from inter-implantation sites.
In this study, we use ovariectomy – induced delayed
implantation and pseudopregnant models as tools to understand
the relative roles played by the embryo and ovarian steroid
hormones in modulating NOS activity in the rat pregnant uterus.
The correlation between NOS and receptive/non-receptive
uterine phases emphasizes the notion that NOS could be locally
regulated in the uterus by pre-implanting and implanting
blastocysts, supporting the possibility that the embryo maintained
high NOS activity both in the receptive uterus and at
implantation. Moreover, the fact that 17b-estradiol and proges-
terone produce similar levels of NOS activity supports the notion
that dormant and activated embryos are capable of modulating
this enzyme. The differences in NOS activity observe between the
three models used in the present work, probably corresponds to
the hormonal treatments employed, which mimics the hormonal
milieu that occurs during normal pregnancy but are not exactly
the same. In accordance with our results, it has been previously
informed that NOS activity is differently regulated in a rat model
in which embryo access to the uterus is impaired [5]. All together
our results suggest that the presence of the embryo within the
uterine lumen and at implantation sites, together with ovarian
hormones, modulate NOS activity during early gestation.
Figure 3. Effect of AEA on NOS activity in the uterus from
pregnant rats. (A) Uterine tissue from day 5 pregnant rats was
incubated for 30 min with AEA 10
29 M. (B) Implantation sites from day
6 of pregnancy were incubated for 15 min with AEA 10
29 M alone or
pre-incubated with selective cannabinoid receptors antagonists.
(C) Inter-implantation sites from day 6 of pregnancy were incubated
with selective cannabinoid receptors antagonists. NOS activity is
expressed as pmoles citrulline mg prot
21 h
21.a :p ,0,001 vs the rest,
b: p,0,001 vs control, antCB2 and antCB1+CB2, c: p,0.05 vs control
and antCB1+antCB2. N=4–6 for each point. antCB1: CB1 selective
antagonist (SR141716A), antCB2: CB2 selective antagonist (SR144528).
doi:10.1371/journal.pone.0018368.g003
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in any mammalian tissue [12,14]. The changing levels of AEA
with changing pregnancy status are consistent with a possible role
for this lipid molecule in early pregnancy. In fact, AEA synthesis
previously described [14–16] is negatively correlated with the
activity of the NOS enzyme describe in the present study. We
Figure 4. Expression of cannabinoid receptor type-1 at implantation and pseudopregnancy. Cannabinoid receptor type-1 (CB1)
messenger (A and C) and protein (B and D) were detected during peri-implantation (A and B) and on day 5 of pseudopregnancy (C and D). Results are
shown as means 6 S.E.M. N=4–6 for each point. a: p,0.001 vs the rest. d4: day 4, d5: day 5, d6: day 6, IM: implantation sites, II: inter-implantation
sites, psp: pseudopregnancy.
doi:10.1371/journal.pone.0018368.g004
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activation participate in the regulation that AEA plays on NOS
activity. In Figure 8 we describe that in the pseudopregnant
model, when the blastocyst is absent, AEA inhibits NOS activity
by binding to CB2 receptors. However, on day 5 of pregnancy,
when the blastocyst apposites over the endometrial endothelium,
AEA does not modify NOS activity. Once embryo invasion
begins, AEA inhibits NOS via CB1 receptors at the sites of
implantation. In the inter-implantation sites, AEA exerts a dual
effect: it inhibits NOS through CB1 and stimulates NOS activity
via CB2. Recently, we have reported that in the placenta obtained
from pregnant rats, AEA also inhibits NOS activity and that this
effect is reversed by CB2 antagonists [37]. An interesting review
has been published, in which the author discussed the different
signalling pathways triggered by CB1 and CB2 in reproduction,
especially those controlling the intracellular tone of nitric oxide
[38]. Furthermore, it has been described in different systems that
while CB1 activates NOS, CB2 inhibits it [17,18]. The opposite
effect of CB1 versus CB2 on NO release might be relevant for the
in vivo control of reproduction, since NO plays several roles in
female fertility [39].
As there are no studies describing the expression pattern of
cannabinoid receptors during the peri-implantation period in the
rat and in order to gain insight into the role of these receptors in
the transduction of crucial signals during implantation, we decided
to describe the temporal pattern of expression and localization of
the anandamide-binding receptors CB1 and CB2 in the rat uterus.
Our results describe for the first time the presence and regulation
of CB1 and CB2 mRNA and protein in the luminal and glandular
endometrium of the rat uterus during the peri-implantation
period.
CB1 messenger clearly decrease at the implantation sites from
day 6 of pregnancy. Although there was no difference after the
blastocyst enters the uterus, there is a clear modulation once
implantation begins, suggesting that the blastocyst would be
regulating CB1 mRNA. When we analyze the expression of CB2
messenger, we observe that once the blastocyst enters the uterus
(day 5 of pregnancy), its level remains constant, and contrary to
what happens with CB1 mRNA, there is no difference between the
implantation and the inter-implantation sites.
CB1 protein is not modulated during gestation as is CB1
messenger. There is no difference after the embryo enters the
uterus or between the implantation and the inter-implantation
sites. It is possible that as real time RT-PCR technique is more
sensible than western blot analyses, the decrease in CB1 expression
at the implantation sites could not be detected at the protein level.
With respect to CB2 protein, it presents a similar pattern as CB2
mRNA: after the embryo enters the uterus (day 5) the protein level
of CB2 remains constant.
Using Northern blot hybridization and reverse transcription-
PCR, the group of Das and colleagues were the first ones to
demonstrate that CB1 mRNA, but not CB2 mRNA, is expressed
in the mouse uterus [40]. Later, in 1998, Buckley described by in
situ hybridization the presence of both CB1 and CB2 mRNA in
the rat placental cone and uterine smooth muscle from days of
gestation 8 to 12 [41]. Recently, it has been described that CB
receptors (CBRs) messenger and protein are expressed in the rat
decidualized cells and placenta during mid and late gestation
[42,43].
Overall, our results suggest that the blastocyst intrinsic program
might operate in conjunction with ovarian hormones regulating
NOS activity via cannabinoid receptors in a specific manner
Figure 5. Localization of cannabinoid receptor type 1 during implantation. Immunolocalization of cannabinoid receptor type-1 (CB1) in
uteri from day 4 (A), day 5 (B), day 6 implantation sites (C) and day 6 inter-implantation sites (D: luminal, E: glandular). Tissue sections were processed
by the immunoperoxidase technique using a polyclonal antibody directed against CB1. No staining was observed in the luminal and glandular
epithelium when the first antibody was omitted (F). Black arrows denote specific staining. The scale bar indicates 20 mm.
doi:10.1371/journal.pone.0018368.g005
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PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e18368Figure 6. Expression of cannabinoid receptor type-2 at implantation and pseudopregnancy. Cannabinoid receptor type-2 (CB2)
messenger (A and C) and protein (B and D) were detected during peri-implantation (A and B) and on day 5 of pseudopregnancy (C and D). Results are
shown as means 6 S.E.M. N=4–6 for each point. a: p,0.01 vs day 5, b: p,0.05 vs day 4. d4: day 4, d5: day 5, d6: day 6, IM: implantation sites, II: inter-
implantation sites, psp: pseudopregnancy.
doi:10.1371/journal.pone.0018368.g006
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PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18368Figure 7. Localization of cannabinoid receptor type 2 during implantation. Immunolocalization of cannabinoid receptor and type-2 (CB2) in
uteri from day 4 (A: luminal and B: glandular), day 5 (C), day 6 implantation sites (D) and day 6 inter-implantation sites (E: luminal, F: glandular). Tissue
sections were processed by the immunoperoxidase technique using a polyclonal antibody directed against CB2. No staining was observed in the
luminal and glandular epithelium when the first antibody was omitted (G). Black arrows denote specific staining. The scale bar indicates 20 mm.
doi:10.1371/journal.pone.0018368.g007
Figure 8. Summary of cannabinoid receptors mediated effects of AEA on NOS activity. For details see description in the Discussion
section.
doi:10.1371/journal.pone.0018368.g008
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PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e18368during implantation. Critical changes in CBRs in the maternal
side of the fetal-maternal interface would occur during implanta-
tion and finally influence the outcome of gestation. We
hypothesize that the degree of CBRs activation together with the
group of molecules activated downstream would finally determine
the function of CB1 and CB2 in each zone of the uterus. AEA
levels close to and at implantation sites modulate NOS activity and
thus NO nitric oxide production, fundamental for implantation,
via CBRs, and this depends on the presence of the blastocyst,
establishing CBRs as an interesting and novel target for the
treatment of implantation deficiencies. On a final note, it should
be recalled that blastocysts’ triggering specific signalling pathways
may exist, which could impact reproductive events in yet-unknown
ways.
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